Google DeepMind, Isomorphic Labs launch bioresilience AI amid DeSci funding gap
In brief
- Google DeepMind and Isomorphic Labs announce joint bioresilience initiative using AI to predict and defend against biological threats.
- Isomorphic Labs raised $2.1 billion Series B funding in May 2026, highlighting scale disparity with decentralized science efforts.
- Initiative excludes tokens, on-chain components, and DAOs, underscoring centralized nature of cutting-edge AI biotech.
Centralized AI, Traditional Pharma
Isomorphic Labs, the drug discovery spinoff founded by DeepMind CEO Demis Hassabis in November 2021, has already partnered with Novartis and Eli Lilly to accelerate AI-driven drug design. The company raised $2.1 billion in a Series B round in May 2026, signaling investor confidence in centralized biotech innovation.
The foundation for this work rests on AlphaFold 3, released in May 2024, which expanded the system's capabilities beyond proteins to model interactions between proteins, DNA, RNA, and small molecules. AI-designed drugs from these collaborations are expected to enter clinical trials by the end of 2026.
The Defensive Turn
The bioresilience initiative adds a defensive dimension to work that has largely been framed around offensive drug discovery. It's a strategic shift—from designing therapeutics to building predictive defenses against biological threats. Institutions like Lawrence Livermore National Laboratory have also been conducting AI-protein research that intersects with this emerging field.
Notably, the initiative involves no tokens, on-chain components, or DAOs funding the work. This matters.
The Scale Mismatch
When a single subsidiary can raise $2.1 billion in one funding round, it reveals the scale mismatch between DeSci ambitions and DeSci resources. The crypto sector has positioned itself as an alternative funding mechanism for biotech research, yet the capital concentration in centralized players remains stark.
For crypto protocols that can credibly position themselves as infrastructure layers for this kind of research—whether through data marketplaces, decentralized compute networks, or IP tokenization—the addressable market is growing. But the gap between DeSci rhetoric and centralized biotech execution continues to widen.
